The company's first product is an IGF-methotrexate conjugate. This involves the standard chemotherapy drug methotrexate chemically attached to an engineered form of the hormone insulin-like growth factor (IGF). The IGF-methotrexate homes in on IGF receptor proteins on cancer cells to specifically deliver the drug to cancer cells. In contrast, healthy cells receive very little drug. Testing in mice shows the IGF-methotrexate conjugate is more effective than methotrexate even when used at 6-times lower dose. We plan to initiate human clinical trials of this drug shortly.

The company plans to develop other novel drugs based on its patent-pending technology, including IGF conjugates with other chemotherapy drugs, therapeutic radioactive isotopes, and toxins to target the drug to cancer cells and kill the cancer cells.